United States //   Management & Directors

Management & Directors

Management & Directors

EXECUTIVE MANAGEMENT
John Onopchenko

John Onopchenko became the Chief Executive Officer in May 2018 after joining us in October 2017 as Chief Operating Officer. With almost thirty years of experience in medical devices, John most recently served as Executive Vice President for Acutus Medical. In 2013, after a decade on the Board of Directors of Volcano Corporation, John stepped off the Board, joined the leadership team and ultimately became the company’s Chief Operating Officer. After Phillips acquired Volcano in March 2015, John was retained by Philips as Senior Vice President and Head of Therapy Strategy. Prior to Volcano John, was a founder and Managing Director of Synergy Life Partners, a medical device venture capital firm. The previous 20 years of John’s career included increasing leadership responsibilities at Johnson & Johnson and GE Healthcare. John received his Bachelors of Science degree from Ursinus College and his MBA from the University of Chicago.

vaseem

Vaseem Mahboob joined in October 2015. Prior to joining Endologix, Mr. Mahboob served in several financial leadership positions at GE Healthcare, a worldwide leader in medical device development and distribution. His most recent role was Chief Financial Officer of their Global IT business. Prior to this position he was the Chief Financial Officer of their Eastern and African Emerging Markets where he oversaw financial operations for medical device distribution sales and service spanning 84 countries and four zones including Russia, Turkey, Middle East and Africa. Prior to this role, Mr. Mahboob was Chief Financial Officer of GE Healthcare's Global Ultrasound Business that is the most global and profitable within GE Healthcare.  Mr. Mahboob also served as CFO of GE Healthcare's Global Magnetic Resonance (MRI) Business, along with several other global financial leadership positions. Mr. Mahboob received a B.A. in Engineering from Bangalore University, and a Masters of Business Administration (MBA) in Financial Markets and Institutions & Information Systems from State University of New York, Buffalo, NY. He is also a graduate of GE's highly regarded internal corporate audit staff where he was a senior audit manager.

Matthew Thompson

Matthew Thompson, M.D., joined in December 2016. Most recently, Dr. Thompson served as Professor of Vascular Surgery at St. George's, University of London and St George's Vascular Institute (SGVI). He trained at Cambridge, St. Bartholomew's Hospital, the University of Leicester and Adelaide. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. Dr. Thompson is also the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services and is a founder of the British Society for Endovascular Therapy. Dr. Thompson is also a Council Member of the Vascular Society, Chairman of the Vascular Society Annual Scientific Meeting and elected President for 2018.

Dave Jennings

Dave Jennings was named Chief Human Resources Officer in July 2018 after serving as VP of Human Resources since 2013. While at Endologix, Dave served as the project leader for the 2016 merger with TriVascular. Mr. Jennings spent twenty-five years as a Human Resources leader with Johnson & Johnson, twelve of those years in medical devices.  At J&J, he served as Vice President, Human Resources for Advanced Sterilization Products in Irvine, CA and for nearly ten years at Neutrogena Corporation in Los Angeles. He has a proven track record of building high performance organizations in fast growing global companies.  He has a diversity of health care experience, to include ophthalmology, surgical products, hospital products, instrument sterilization, pharmaceuticals and consumer products.   After leaving J&J, Dave held HR Vice President roles in the Entertainment Industry as well as in a health care start-up venture in Southern California.  Dave holds a Masters in Business from Claremont Graduate University.

Jeremy Hayden

Jeremy Hayden joined us in August 2017 as General Counsel. Prior to Endologix, Jeremy served as General Counsel and VP Business Development for Cytori Therapeutics, a company focused on cell therapy and nanomedicine. Prior to Cytori, Jeremy served as Assistant General Counsel for Volcano Corporation. Volcano was acquired by Royal Phillips for approximately $1.2 billion in February 2015. Prior to his tenure at Volcano, Jeremy practiced corporate and securities law at several international law firms, including Brobeck, Phleger & Harrison LLP and Mintz Levin Cohn Ferris Glovsky & Popeo, PC. Mr. Hayden received his A.B. in Politics from Princeton University and his J.D. from the University of Michigan Law School.

Jeff Brown COO web
Jeff Brown joined Endologix in August 2018 bringing twenty-four years of experience as a General Manager, Chief Operating Officer, Supply Chain Executive, Sales Leader, Consultant and Lecturer. Most recently, he was General Manager of a multi-site joint venture between Johnson & Johnson and Steris Corporation where he led significant improvements across operations, quality, engineering, and supply chain. Prior to that, he was COO of Chatham Industries, where he helped successfully orchestrate a leveraged buyout and turnaround of the firm. Prior to that, Jeff worked for five years as General Manager at Boston Scientific Corporation, where he led a critical site transformation and sat on the global supply chain management board. Jeff also worked for seven years as Worldwide Operations Manager at Johnson & Johnson and for five years leading sterilization operations across the U.S., EU, and Far East for Haemonetics Corporation. Jeff earned his MBA from Babson College in Wellesley, Massachusetts and his Bachelor of Science degree in Microbiology from the University of New Hampshire in Durham, NH.
Fecho Image

Jeff Fecho joined in June 2018. Most recently, he was the Division Vice President for Operations and New Product Quality at Abbott, where he led the global Quality organization for 20 sites and the New Product Development function. Previously, Jeff was the top Quality Officer for St. Jude Medical, where he worked for more than eleven years. At St. Jude, as Vice President, Global Quality, Jeff was responsible for the oversight, remediation, best practice propagation and the education and evangelism of quality. Jeff’s prior experience with cardiovascular products was with Boston Scientific Corporation, where he had Quality Operations and R&D positions. Jeff is an ASQ Certified Six Sigma Black Belt and received his Bachelors of Science degree in Industrial Technology from East Carolina University and his MBA from Elon College in North Carolina.

Chobotov

Michael V. Chobotov, Ph.D. joined us in February 2016 in conjunction with the merger of TriVascular.  He co-founded TriVascular as President and CEO in 1998, while creating the foundation for polymer endograft technology. He led the company’s spin-off from Boston Scientific Corporation in 2008, and continued to serve as President/CEO and member of the board of directors until 2012. Prior to co-founding TriVascular in 1998, Dr. Chobotov co-founded TransMotive Technologies, an engineering and product development consulting company. Previously, Dr. Chobotov served as Senior Vice President of R&D and board member of U.S. Electricar, and Senior Systems Engineer at Hughes Space and Communications. He also led the design of the Lunar Prospector, which was subsequently implemented as the first NASA Discovery mission. Dr. Chobotov received his Ph.D. in Mechanical Engineering, his M.S. in Mechanical Engineering and his B.S. in Engineering and Applied Science, all from the California Institute of Technology.

DeJohn

Joseph A. DeJohn joined in July 2008. He has more than 20 years of sales management experience in the medical device industry, including serving 17 years at C.R. Bard. During his tenure at C.R. Bard, he held sales management positions with increasing responsibilities, serving the last six years as Vice President of Sales of the Peripheral Vascular Division. In this position, he was responsible for managing a 200-person sales organization and played a leadership role in strategic planning, budgeting, recruitment, professional development, national accounts, and customer service. Prior to that, Mr. DeJohn was Director of Sales of C.R. Bard's Peripheral Technologies Division. Before joining C.R. Bard, Mr. DeJohn served five years with Bausch & Lomb Corporation in various sales management positions. Mr. DeJohn holds a B.S. in Education from Bowling Green State University.

Elisa Hebb
Elisa Hebb joined Endologix in August 2018 with more than twenty years of success in Clinical Research and Regulatory Affairs. She has led the development and execution of global clinical studies for both Class II and Class III medical devices in addition to leading regulatory strategies, and submissions for US and international agencies. Elisa comes to us from Spirox where she was responsible for clinical and regulatory and was the Compliance Officer. Previously, Elisa was the Senior Director of Global Clinical Affairs and Clinical Development for Philips Volcano. Prior vice presidential roles held by Elisa include Atheromed, Crux Biomedical and Apneon. Prior experience is largely in the vascular and electrophysiology with such companies as Boston Scientific, Vascular Architects and ACS. Elisa earned her Bachelor’s degree from UC Berkeley.
valerie tansley

Valerie LS Tansley joined Endologix in March 2014. Valerie has over 30 years of experience in the life sciences industry, starting her career in R&D at Johnson & Johnson developing DNA-based diagnostic test kits. This was followed by 26 years at Edwards Lifesciences (previously a Baxter Healthcare company), a global leader in patient-focused innovations, where she held positions in the Critical Care division with increasing responsibility across a wide variety of functions, including Baxter corporate business development, marketing, continuous improvement, supply chain, R&D, leading a divesture team, and leading the new product development project management office. Upon joining Endologix, Valerie led the Nellix commercialization/PMA efforts, then revitalized our Lean/Six Sigma program, including leading global Lean and Black Belt projects. Most recently she was a Sr. Director in Human Resources responsible for the Irvine site, talent acquisition, performance management, and HR Administration teams. Valerie has a proven track record of using her broad functional experience to build high performance teams and deliver on objectives. Valerie earned her B.A. in Biochemistry/Molecular Biology from the University of California, Santa Barbara and her M.B.A. from Pepperdine University.

brian chambless headshot
Brian Chambless joined in October 2005. He has more than 20 years of sales and leadership experience, including 18 years in the vascular/endovascular space. During his tenure with Endologix, he held sales management positions with increasing responsibilities, serving the last seven years as Director of Sales. Prior to joining Endologix, Brian spent five years at Boston Scientific in the Peripheral Vascular division. Expertise include sales, marketing, training, commercial strategy and sales team development in both the large company and start up environment. Brian holds a B.S. in Business Management from the University of Alabama.
BOARD OF DIRECTORS
Dan Lemaitre

Dan Lemaitre most recently served as the President and CEO of Direct Flow Medical. Previously, Mr. Lemaitre was the CEO of CoreValve, one of the early pioneers in transcatheter aortic valves.  By 2009 revenue were at a $100 million annualized end market run rate.  Dan led negotiations that resulted in the sale of CoreValve to Medtronic in a transaction valued at $800 million.

Prior to joining CoreValve, Mr. Lemaitre was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development.  Dan was also a member of Medtronic’s executive and operating committees.    

In 2012 Dan was part of an investor syndicate that took private a $250 million division of a major orthopedic company and served as its initial Chairman.   He is also on the board of Globus Medical  (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$600 million per annum.  Dan serves on the Globus audit and compensation committees.

Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.  He began his career as a buy-side analyst in 1978 working at National City Bank in Cleveland and later, Standish Ayer & Wood in Boston.  His sell-side career included 18 years with Cowen & Company, where he was a managing director and led the health care research team.  In 1999, Dan moved his team to Merrill Lynch where he headed-up the medical technology effort for six years.  During his Wall Street tenure, Dan was named to Institutional Investor’s All American research team for 19 consecutive years, capturing first place honors 8 times as the top-ranked medical device analyst in the country. 

Dan has a BA in Economics (1976) from Bethany College (West Virginia) and an MBA (1978) from Bowling Green State University in Ohio.  He earned a Chartered Financial Analyst (CFA) in 1982.   

Guido Neels

Mr. Guido Neels has served on our board of directors since December 2010. Mr. Neels is an Operating Partner at Essex Woodlands. Prior to joining Essex Woodlands in 2006, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005, Mr. Neels served as Guidant's Chief Operating Officer, where he was responsible for the global operations of Guidant's four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 to July 2004, Mr. Neels served as Guidant's Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000, Mr. Neels was named Guidant's President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant's Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant's General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels has a business engineering degree from the University of Leuven in Belgium and an M.B.A. from the Stanford University Graduate School of Business. Mr. Neels served on the boards of directors of Biopure Corporation, a publicly-traded medical device company, from 2005 to 2009, Lemaitre Vascular, Inc., a publicly-traded medical device company, from 2006 to 2008, and Nellix, Inc., a privately-held medical device company, from 2006 until its acquisition by us in December 2010. Mr. Neels currently serves on the boards of directors of AxoGen, Inc. and Entellus Medical, Inc., both publically held companies as well as 480 Biomedical, Inc., Arsenal Medical, Inc., and White Pine Medical, Inc., all privately-held medical device companies. He also serves on the board of Christel House International, a not-for-profit organization. Mr. Neels was appointed to our board of directors pursuant to a board designation right granted to Essex Woodlands Health Ventures Fund VII, L.P., or Essex Woodlands Fund VII, a stockholder of our company and an affiliate of Essex Woodlands, under a securities purchase agreement, dated as of October 27, 2010, as amended December 9, 2010, between us and Essex Woodlands Fund VII.

Leslie Norwalk

Ms. Leslie Norwalk has served on our board of directors since 2015. Ms. Norwalk currently serves as a Strategic Advisor and Strategic Counsel to the law firm Epstein Becker & Green, P.C., healthcare and life science consultancy EBG Advisors, Inc., and legislative and regulatory consultancy National Health Advisors. Ms. Norwalk is also an Operating Partner at Enhanced Equity Fund, L.P. and serves as an Advisor to Warburg Pincus LLC, and Peloton Equity. Previously, Ms. Norwalk served the Bush Administration as the Acting Administrator for the Centers for Medicare & Medicaid Services, where she managed the day-to-day operations of Medicare, Medicaid, State Child Health Insurance Programs, Survey and Certification of health care facilities and other federal health care initiatives. For four years prior to that, she was the agency’s Deputy Administrator, responsible for the implementation of the changes made under the Medicare Modernization Act, including the Medicare Prescription Drug Benefit. Prior to serving the Bush Administration, Ms. Norwalk practiced law in the Washington, D.C. office of Epstein Becker & Green, P.C. where she advised clients on a variety of health policy matters. She also served in the first Bush administration in the White House Office of Presidential Personnel, and the Office of the U.S. Trade Representative. Ms. Norwalk also serves as Member of International Advisory Council at APCO Worldwide Inc. She earned a J.D. degree from the George Mason University School of Law and a bachelor’s degree, cum laude, in Economics and International Relations from Wellesley College.

Gregory Waller

Gregory D. Waller has served on our board of directors since November 2003. Mr. Waller also serves on the board of Sunshine Heart Corporation, a publicly traded company, as Audit Committee Chairman and was the Chief Financial Officer of Ulthera Corporation, a privately held company that sells an ultrasound device used for non-invasive brow lifts from October of 2011 until its acquisition by Merz GMBH. He retired from Ulthera in April of 2015. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Previous to that, Mr. Waller has been in retirement except for board directorships. Mr. Waller served as Vice President-Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from August 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller joined Ormco Corporation in December 1980 as Vice President and Controller and served as Vice President of Kerr European Operations from July 1989 to August 1993. Mr. Waller has an M.B.A. with a concentration in Accounting from California State University, Fullerton. Mr. Waller also served on the board of directors and audit committee of Cardiogenesis Corporation, a publicly-traded company until its acquisition by Cryolife in 2011. Mr. Waller also served on the boards of directors of Alsius Corporation, a publicly-traded company, from June 2007 to September 2009 until its acquisition by Zoll, Biolase Technology, Inc., a publicly-traded company, from October 2009 to August 2010, Clarient, Inc., a publicly-traded company which was acquired by General Electric Company on December 22, 2010, and SenoRx, Inc., a publicly-traded company which was acquired by C.R. Bard, Inc. on July 6, 2010.

Thomas Wilder

Thomas Wilder has served on our board of directors since May 2010. He currently also serves on the board of Penumbra Inc. (PEN), a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices, and on the board of Benvenue Medical Inc., a privately-held medical device company focused on the design, manufacture, and marketing of cutting edge products for the rapidly growing minimally invasive spinal surgery market.  From February 2010, Mr. Wilder served as President and Chief Executive Officer of Sequent Medical, Inc., until it was acquired by Terumo Corporation in July 2016.  From May 2009 to January 2010, Mr. Wilder consulted with several medical device companies. From April 2006 to April 2009, Mr. Wilder served as President and Chief Executive Officer of Photothera, Inc. From 2002 through January 2006, Mr. Wilder served at Micro Therapeutics, Inc. (MTIX) as President and Chief Executive Officer. Following the merger of Micro Therapeutics, Inc. into ev3 Inc. in January 2006, Mr. Wilder served as President, ev3 Neurovascular until April 2006. From 1991 to 2002, Mr. Wilder served in various roles for Medtronic, Inc. Mr. Wilder has a B.A. in Economics from Stanford University and an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management.

Thomas Zenty

Thomas F. Zenty, III has served on our board of directors since May 2013. He is currently the President and Chief Executive Officer of University Hospitals Health System, Inc., Cleveland, OH.  Previously, Mr. Zenty held various executive positions at Cedars-Sinai Health System, St. Josephs Medical Center, a division of Catholic Health Care West, Franciscan Health System of New Jersey and St. Mary Hospital, Connecticut.  Mr. Zenty is Chairman of the Board of Western Reserve Assurance Company, Ltd. SPC, a privately-held insurance company and chairs The Coalition to Protect American’s Health Care.  Mr. Zenty is a past board member of the American Hospital Association and has also served on the board of directors of Nationwide Financial Services and Amerimed. Mr. Zenty has held several academic positions with prestigious universities, including his current position as Adjunct Professor, Banking & Finance at Case Western Reserve University.  He received a Master’s degree in Public Administration from New York University, a Master’s degree in Hospital Administration from Xavier University, and a Bachelor’s degree in Health Planning from Pennsylvania State University.

John Onopchenko

John Onopchenko became the Chief Executive Officer in May 2018 after joining us in October 2017 as Chief Operating Officer. With almost thirty years of experience in medical devices, John most recently served as Executive Vice President for Acutus Medical. In 2013, after a decade on the Board of Directors of Volcano Corporation, John stepped off the Board, joined the leadership team and ultimately became the company’s Chief Operating Officer. After Phillips acquired Volcano in March 2015, John was retained by Philips as Senior Vice President and Head of Therapy Strategy. Prior to Volcano John, was a founder and Managing Director of Synergy Life Partners, a medical device venture capital firm. The previous 20 years of John’s career included increasing leadership responsibilities at Johnson & Johnson and GE Healthcare. John received his Bachelors of Science degree from Ursinus College and his MBA from the University of Chicago.